Current Concepts

Venous Thromboembolism in Lower Extremity Arthroscopy

Brandon D. Bushnell, M.D., Adam W. Anz, M.D., and Jack M. Bert, M.D.

Abstract: Venous thromboembolism (VTE) is a relatively rare complication of arthroscopic surgery of the lower extremity, but it does have the potential to result in significant morbidity and possible mortality. VTE has been reported to occur with knee arthroscopy, and guidelines for VTE prophylaxis before and after knee arthroscopy have been proposed. There are much fewer data regarding the incidence of VTE occurring after arthroscopy of the ankle and the hip. This article reviews the literature on the incidence, treatment, and prevention of VTE in association with arthroscopy of the lower extremity. Key Words: Arthroscopy—Deep venous thrombosis—Lower extremity—Prophylaxis—Pulmonary embolism—Venous thromboembolism.

Arthroscopy has long been perceived as low-risk surgery relative to other areas of orthopaedics, such as total joint replacement and trauma. Reported rates of venous thromboembolism (VTE) in association with lower extremity arthroscopy range from 0% to 17.9%. However, reported rates of pulmonary embolism (PE) and deep venous thrombosis (DVT) associated with total joint replacement in the absence of prophylaxis have approached 30% and 70%, respectively. Anticoagulation prophylaxis improves the incidence to approximately 0% for PE and 1.5% for DVT, but VTE still remains a major concern for every arthroscopic surgeon.

Considerable controversy exists within the orthopaedic community regarding prophylaxis of VTE in patients undergoing total joint replacement. Multiple studies have been performed within this population, each with its own recommendations. The Seventh American College of Chest Physicians (ACCP) Conference on Antithrombotic and Thrombolytic Therapy performed an in-depth meta-analysis of these voluminous data and published guidelines for care. However, these data nevertheless remain controversial. The American Academy of Orthopaedic Surgeons (AAOS) has also established its own guidelines for the prevention of VTE in total joint arthroplasty of the hip and knee. VTE in arthroscopic surgery has not garnered the same level of concern, yet it remains an important cause of morbidity and even reported cases of mortality. This article reviews the relevant literature on VTE associated with lower extremity arthroscopy.

HIP ARTHROSCOPY

In a review article regarding hip arthroscopy published 20 years ago, Hawkins warned that “systemic complications, such as pulmonary emboli, must always be considered.” In multiple series of hip arthroscopy cases published in the past 2 decades, however, PE or DVT has simply not been reported. No currently published study has specifically focused on this issue, but a review of more than 5,500 cases in the literature has revealed a 0% rate of DVT and PE (Table 1).
Specific recommendations for prophylaxis of VTE in hip arthroscopy have not been reported. Numerous authors have discussed VTE prophylaxis in other surgical procedures of the hip, but applying these data to hip arthroscopy is inappropriate because of fundamental differences in the type of surgical procedures and in the patient populations. Rather than emphasizing the arthroscopic procedure itself as a risk factor, the surgeon should instead focus on factors related to the patient’s medical history and current medical condition. Most of these risk factors have been well described throughout the medical and surgical literature (Table 2). Decisions regarding anticoagulation prophylaxis for hip arthroscopy should be made on an individualized patient basis and documented in the medical record.

**ANKLE ARTHROSCOPY**

As in hip arthroscopy, ankle arthroscopy has a low rate of VTE. While not specific for ankle arthroscopy, a 0.2% to 4% incidence of VTE has been reported in association with all types of foot and ankle surgery. A review of recent literature specific for ankle arthroscopy confirms that this very low incidence rate can indeed be extrapolated to arthroscopic ankle surgery. In 15 studies involving more than 1,300 patients total, no DVT or PE was reported (Table 3).

Three particular studies of VTE in ankle surgery in general merit discussion in light of their relevance to arthroscopic ankle surgery. Mizel et al. performed a prospective, multicenter analysis of the rate of VTE in 2,373 patients undergoing various procedures of the foot and ankle. They reported a 0.22% incidence of VTE, including a 0.15% rate of non-fatal pulmonary embolus. Patients were diagnosed by clinical examination alone. The authors found that postoperative immobilization and non-weight-bearing status statistically correlated with an increased risk of VTE. They also performed a cost–benefit analysis of screening tests and prophylaxis for VTE, and they concluded that neither is justified in routine clinical care.

Solis and Saxby published a prospective study in which 201 consecutive patients undergoing general foot and ankle surgery received duplex ultrasound testing. No prophylaxis for VTE was used in any of the patients, and no event of VTE was reported.

### Table 1. Reported Incidence of Venous Thromboembolism in Hip Arthroscopy

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>No. of Patients</th>
<th>DVT/PE Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glick et al.</td>
<td>1987</td>
<td>12</td>
<td>0%</td>
</tr>
<tr>
<td>Small</td>
<td>1988</td>
<td>14</td>
<td>0%</td>
</tr>
<tr>
<td>Funke and Munzinger</td>
<td>1996</td>
<td>19</td>
<td>0%</td>
</tr>
<tr>
<td>Byrd and Cherni</td>
<td>1997</td>
<td>11</td>
<td>0%</td>
</tr>
<tr>
<td>Baber et al.</td>
<td>1999</td>
<td>328</td>
<td>0%</td>
</tr>
<tr>
<td>Griffin and Villar</td>
<td>1999</td>
<td>640</td>
<td>0%</td>
</tr>
<tr>
<td>Byrd and Jones</td>
<td>2000</td>
<td>38</td>
<td>0%</td>
</tr>
<tr>
<td>McCarthy et al.</td>
<td>2001</td>
<td>436</td>
<td>0%</td>
</tr>
<tr>
<td>Dienst et al.</td>
<td>2001</td>
<td>35</td>
<td>0%</td>
</tr>
<tr>
<td>O’Leary et al.</td>
<td>2001</td>
<td>86</td>
<td>0%</td>
</tr>
<tr>
<td>Sampson</td>
<td>2001</td>
<td>530</td>
<td>0%</td>
</tr>
<tr>
<td>Byrd</td>
<td>2003</td>
<td>265</td>
<td>0%</td>
</tr>
<tr>
<td>Clarke et al.</td>
<td>2003</td>
<td>1,054</td>
<td>0%</td>
</tr>
<tr>
<td>Keeney et al.</td>
<td>2004</td>
<td>102</td>
<td>0%</td>
</tr>
<tr>
<td>McCarthy</td>
<td>2004</td>
<td>1,475</td>
<td>0%</td>
</tr>
<tr>
<td>Pasa et al.</td>
<td>2005</td>
<td>24</td>
<td>0%</td>
</tr>
<tr>
<td>Yamamoto et al.</td>
<td>2005</td>
<td>10</td>
<td>0%</td>
</tr>
<tr>
<td>Yamamoto et al.</td>
<td>2005</td>
<td>30</td>
<td>0%</td>
</tr>
<tr>
<td>Awan and Murray</td>
<td>2006</td>
<td>22</td>
<td>0%</td>
</tr>
<tr>
<td>Lo et al.</td>
<td>2006</td>
<td>73</td>
<td>0%</td>
</tr>
<tr>
<td>Jerosh et al.</td>
<td>2006</td>
<td>22</td>
<td>0%</td>
</tr>
<tr>
<td>Mullins and Dahners</td>
<td>2006</td>
<td>36</td>
<td>0%</td>
</tr>
<tr>
<td>Owens and Busconi</td>
<td>2006</td>
<td>11</td>
<td>0%</td>
</tr>
<tr>
<td>Bushnell et al.</td>
<td>2007</td>
<td>156</td>
<td>0%</td>
</tr>
<tr>
<td>Kim et al.</td>
<td>2007</td>
<td>43</td>
<td>0%</td>
</tr>
<tr>
<td>Philippin et al.</td>
<td>2007</td>
<td>45</td>
<td>0%</td>
</tr>
<tr>
<td>Philippin et al.</td>
<td>2007</td>
<td>37</td>
<td>0%</td>
</tr>
<tr>
<td>Total</td>
<td>—</td>
<td>5,554</td>
<td>0%</td>
</tr>
</tbody>
</table>

**Abbreviations.** DVT, deep venous thrombosis; PE, pulmonary embolism.

### Table 2. General Risk Factors for Venous Thromboembolism

- Advanced age
- Personal or family history of previous deep venous thrombosis or pulmonary embolism
- Major systemic trauma
- Lower extremity trauma
- Prolonged immobilization
- Full or partial paralysis of lower extremities
- Central venous catheterization
- Obesity
- Tobacco use
- Cancer
- Pregnancy or postpartum status
- Hormonal contraceptive use
- Hormone replacement therapy
- Treatment with selective estrogen receptor modulators
- Known thrombophilic condition
- Varicose veins
- Acute medical illness
- Heart failure
- Respiratory failure
- Inflammatory bowel disease
- Myeloproliferative disorders
- Nephrotic syndrome
- Paroxysmal nocturnal hemoglobinuria
these patients. Deep calf vein thrombi were diagnosed in 7 patients, representing a 3.5% incidence rate. The authors concluded that postoperative immobilization, surgery of the hindfoot, increased tourniquet time, and advanced age all were risk factors for VTE.

Hanslow et al. reported on a retrospective review of 602 patients undergoing general foot and ankle surgery utilizing VTE prophylaxis which varied depending on the treating surgeon. The diagnosis of VTE was made by clinical exam, and a 4% incidence of VTE was reported. A significantly increased risk was present in cases involving postoperative immobilization, previous DVT, rheumatoid arthritis, and recent air travel.

As in hip arthroscopy, screening patients for VTE risk in ankle arthroscopy involves the evaluation of general medical risk factors (Table 2). No specific studies of VTE in isolated arthroscopic ankle cases have been reported, but unique risk factors can be extrapolated from a small number of studies focusing on ankle surgery in general (Table 4). Orthopaedic surgeons should consider some sort of VTE prophylaxis when these risk factors are present, but no guidelines or studies have been reported regarding the choice of prophylaxis.

KNEE ARTHROSCOPY

The majority of the literature regarding VTE of lower extremity arthroscopy involves the knee. The two major groups of studies that exist are those determining the incidence of VTE without prophylaxis and those evaluating the prophylactic benefit of low-molecular weight heparin (LMWH). The remaining literature involves case reports and small series illustrating important considerations in medical management. Upon a thorough review of the literature, the incidence of VTE associated with knee arthroscopy ranges from 0% to 17.9% (Table 5).

Incidence

Articles associating VTE and knee arthroscopy include those that have reported both the incidence of DVT and/or PE. Some of these studies published the incidence of thromboembolic events as their

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>DVT PE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jackson and Abe</td>
<td>1972</td>
<td>1.4% 0.5%</td>
</tr>
<tr>
<td>McGinty et al.</td>
<td>1977</td>
<td>7.3% 0%</td>
</tr>
<tr>
<td>Carson</td>
<td>1979</td>
<td>4.9% 1.6%</td>
</tr>
<tr>
<td>Guhl</td>
<td>1979</td>
<td>1.0% 0%</td>
</tr>
<tr>
<td>Lysholm et al.</td>
<td>1981</td>
<td>1.0% 0%</td>
</tr>
<tr>
<td>Dandy and O’Carroll</td>
<td>1982</td>
<td>0.3% 0%</td>
</tr>
<tr>
<td>Mulhollan</td>
<td>1982</td>
<td>0.3% 0.02%</td>
</tr>
<tr>
<td>DeLee</td>
<td>1985</td>
<td>0.1% 0.03%</td>
</tr>
<tr>
<td>Rand</td>
<td>1985</td>
<td>3.4% 0%</td>
</tr>
<tr>
<td>Coudane et al.</td>
<td>1986</td>
<td>0.75% 0.25%</td>
</tr>
<tr>
<td>Collins</td>
<td>1989</td>
<td>0.3% 0.06%</td>
</tr>
<tr>
<td>Stringer et al.</td>
<td>1989</td>
<td>4.2% 0%</td>
</tr>
<tr>
<td>Williams et al.</td>
<td>1995</td>
<td>3.5% 0%</td>
</tr>
<tr>
<td>Cullison et al.</td>
<td>1996</td>
<td>1.5% 0%</td>
</tr>
<tr>
<td>Durica et al.</td>
<td>1997</td>
<td>3.2% 0%</td>
</tr>
<tr>
<td>Demers et al.</td>
<td>1998</td>
<td>17.9% 0%</td>
</tr>
<tr>
<td>Delis et al.</td>
<td>2001</td>
<td>7.8% 0%</td>
</tr>
<tr>
<td>Berquist and Lowe</td>
<td>2002</td>
<td>4.2% 0%</td>
</tr>
<tr>
<td>Ng et al.</td>
<td>2005</td>
<td>1.2% 0%</td>
</tr>
<tr>
<td>Hoppener et al.</td>
<td>2006</td>
<td>5.7% 0.003%</td>
</tr>
<tr>
<td>Reigstad and Grimsgaard</td>
<td>2006</td>
<td>0% 0.17%</td>
</tr>
</tbody>
</table>

Abbreviations. DVT, deep venous thrombosis; PE, pulmonary embolism.
primary focus, while others reported it secondarily as part of a study with a different goal. The incidence of VTE, DVT, and PE differs significantly among various studies based upon multiple factors, including patient age, medical history, and type of surgical procedure performed. The literature and its reports of incidence reflect the changes in VTE management over the last 3 decades. In the 1980s and 1990s, published studies regarding the incidence of VTE and knee arthroscopy reported the diagnosis based upon clinical signs and symptoms—a method which suffers from low sensitivities and specificities. Recent articles have reported that 40% to 50% of cases of DVT diagnosed by ultrasound or venogram were clinically asymptomatic, implying that the earlier studies may have missed several cases of VTE. In more recently published articles, however, the diagnosis has been based upon the objective results of venography and/or ultrasound.

Perhaps the best overall analysis of VTE incidence after knee arthroscopy in patients without prophylaxis is a meta-analysis by Ilahi et al. which included a review of six studies and a total of 684 patients. This meta-analysis suggested an overall DVT rate of 9.9% and a proximal DVT rate of 2.1%. Criteria for inclusion in the meta-analysis were screening for DVT with ultrasound or venography and the exclusion of concomitant ligament repair or open knee surgical procedures.

Obviously, the general medical risk factors for VTE incidence also apply to knee arthroscopy (Table 2). A direct assessment of some of these factors has been performed in some studies specific to knee arthroscopy. Demers et al. performed an analysis which included age, sex, family history of VTE, previous personal history of VTE, home medications, anesthesia, duration of surgery, duration of immobilization, and tourniquet time. Despite a review of all of these risk factors, only a tourniquet time of greater than 60 minutes was found to be a statistically significant factor associated with the development of VTE. Delis et al. studied the following criteria: age greater than 65 years, body mass index over 30, smoking, hormone replacement or contraceptive use, history of chronic venous insufficiency, and history of previous VTE. In this series, the only statistically significant single risk factor was a history of previous VTE. The authors also concluded that two or more general risk factors for hypercoagulability increased the risk of VTE after knee arthroscopy.

Prophylaxis

The second major group of articles regarding VTE in knee arthroscopy involves a series of studies regarding prophylactic options. There are three published randomized, controlled trials and three cohort studies that have assessed prophylaxis with LMWH after knee arthroscopy. While results have varied slightly between these studies, the overall consensus seems to be that LMWH is effective at reducing VTE risk.

Wirth et al. followed 239 total patients and randomized them into matched groups: 117 receiving reviparin for 7 to 10 days after surgery and 122 receiving no treatment. DVT was diagnosed by color-coded sonography. There was a VTE incidence of 0.85% in the reviparin group and 4.1% in the control group, correlating with a relative risk reduction of 80%. The single patient with a DVT in the reviparin group was found to have low levels of protein C and protein S, indicating a possible coagulopathy. There were no patients with major bleeding episodes in the reviparin group.

Michot et al. published a similar study involving 130 patients randomized into two groups: 66 treated with dalteparin and 64 without prophylaxis. The first dose of LMWH was given just before surgery and continued daily for 4 weeks. DVT was diagnosed by compression ultrasonography. There was a VTE incidence of 15.6% without prophylaxis and 1.5% with prophylaxis. This represented a statistically significant risk reduction for VTE (P = .004). The authors reported that 80% of all DVTs were diagnosed within the first 2 weeks after surgery.

Marlovits et al. reported on 175 patients undergoing arthroscopic anterior cruciate ligament repair. All patients received enoxaparin preoperatively and during their 3- to 8-day postoperative hospitalization. Patients were then randomized into two groups: 87 patients receiving enoxaparin and 88 receiving placebo for 3 weeks after discharge. This study employed magnetic resonance venography to evaluate for DVT and lung scans to evaluate for PE. There was a 2.8% incidence of DVT in patients treated with enoxaparin, compared to a 41.2% incidence of DVT of those receiving placebo. This represented a statistically significant reduction in risk of DVT with enoxaparin (P < .001). There was no statistically significant difference in bleeding events between the two groups, and there were no cases of PE. After an analysis of risk factors, this study concluded that age greater than 30
years and immobilization before surgery were statistically significant for increased risk of VTE.

Three other studies focusing on VTE prophylaxis did not involve a randomized, controlled design but still merit discussion here. Schippinger et al. and Obernosterer et al. followed a cohort of 101 patients who received dalteparin after knee arthroscopy. Ultrasound, phlebography, and lung scans were used to screen for DVT and PE. This study reported a 12% rate of VTE. Three patients had DVT, 4 patients developed PE, and 5 patients had both DVT and PE. This study reported an increased rate of VTE in spite of LMWH prophylaxis, which is especially concerning in that 4 of the 8 DVTs and 8 of the 9 PEs were clinically silent. There was no correlation with tourniquet time, anesthetic type, or duration of surgery with the incidence of DVT.

Holland and Schain reviewed 102 patients who underwent postoperative prophylactic treatment with nadroparin for 5 to 6 days after knee arthroscopy. There was a 4.9% rate of symptomatic DVT in spite of prophylaxis with LMWH. Eighty percent of the DVTs occurred after prophylactic treatment was terminated.

Montebugnoli et al. reported no proximal DVT or other thromboembolic events in a study of 509 patients receiving paranoparin after minor arthroscopic knee surgery. The authors recommended treatment with the LMWH for 10 days after surgery. There were 8 adverse events related to the paranoparin, however, raising some concern about the risk–benefit ratio of treatment.

Future research is required to determine if the benefits of prophylaxis for VTE after knee arthroscopy outweigh the risks and costs. However, the randomized, controlled trials of LMWH prophylaxis seem to support its use in decreasing the risk of VTE after knee arthroscopy. Yet the cohort studies illustrate that multiple issues must be resolved before definitive prophylactic treatment recommendations can be made. A recent Cochrane Database review highlighted the inability of the current literature to definitively support thromboprophylaxis of any type, and recommended that future studies perform more organized stratification of patients by risk factor and type of procedure. The type of LMWH, duration of therapy, timing of therapy (preoperative and postoperative), method of DVT/PE diagnosis, and screening for other risk factors may all play a role in the analysis of LMWH efficacy and also must be considered. Although future studies will be required to determine the appropriate methodology of using LMWH, this treatment currently represents the best literature-supported option for prophylaxis. Specific indications for LMWH use thus remain to be more clearly defined. In addition, while the use of other methods such as aspirin, warfarin, heparin, and multimodal prophylaxis have all been well described in relation to total joint arthroplasty, no studies have focused on their use specifically for arthroscopy.

**Fatal Pulmonary Embolism**

As evidenced by the literature discussed earlier, PE appears to be a very rare occurrence in association with knee arthroscopy, and most cases of PE are clinically silent or respond to treatment. Several case reports of fatal PE exist in which one or more risk factors were present for VTE. In some cases, however, the only risk factor may have been the arthroscopy itself (i.e., lower extremity surgery as a risk factor). For example, a fatal PE was reported by Navarro-Sanz and Fernandez-Ortega in a 46-year-old man who had no known risk factors other than his orthopaedic procedure, which involved a tourniquet time of only 35 minutes. This case serves as a reminder of the importance of always considering the potential risk of VTE in every surgical case, appropriately discussing the possibility of this complication with the patient preoperatively, and documenting that discussion in the medical record.

Another recent case report by Janssen and Sala involved a 17-year-old female soccer player who suffered a fatal PE after an anterior cruciate ligament reconstruction. This patient had identifiable risk factors of oral contraceptive use and family history of coagulopathy. This case raises the question of whether or not to discontinue oral contraceptives before and after knee arthroscopy. Berg and Montanarella recommended that oral contraceptive pills be continued with the addition of chemoprophylaxis in patients undergoing knee arthroscopy—arguing that the risk of pregnancy-related death as a consequence of unprotected sex is higher than the risk of death as a complication of oral contraceptive use.

**CONCLUSIONS**

VTE remains one of the most feared potential complications of arthroscopy of the lower extremity. There have been no reports of cases of DVT or PE associated with hip or ankle arthroscopy to date, and thus the surgeon should base prophylaxis decisions before these procedures on the existing medical factors associated with each individual patient. The vast
majority of existing data about VTE prophylaxis in lower extremity arthroscopy pertains to the knee, including specific guidelines and recommendations. The incidence of VTE associated with knee arthroscopy appears to be approximately 10% and can be reduced with the use of prophylactic LMWH. Presently, however, the guidelines of the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy remain the only current official recommendations that are specific to knee arthroscopy. The guidelines recommend prophylaxis with LMWH only when patients have pre-existing risk factors for hypercoaguability or after a complicated/prolonged procedure.4 Further research is required to evaluate thromboembolic disease in lower extremity arthroscopy, with attention to specifics such as indications, risks, benefits, dosages, intervals, costs, and other features of various prophylactic options.

REFERENCES

24. McCarthy JC. Hip arthroscopy: When it is and when it is not indicated. Instr Course Lect 2004;53:615-621.
36. Philippon MJ, Schenker ML, Briggs KK, Kuppersmith DA,


Obernosterer A, Schippinger G, Lipp RW, Wimserberger G,


